Will Applied Dna Sciences (BNBX) stock go up?

According to Danelfin AI, Applied Dna Sciences (BNBX) has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (38.26%) is -12.56% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Applied Dna Sciences (BNBX) stock?

The Applied Dna Sciences (BNBX) target price is $1.06K (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Applied Dna Sciences (BNBX) stock right now?

Applied Dna Sciences (BNBX) has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (38.26%) is -12.56% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Applied Dna Sciences (BNBX) stock is a good buy .

Is Applied Dna Sciences (BNBX) undervalued right now?

Based on analysts, the average price target upside for Applied Dna Sciences (BNBX) is +288,361.55% (1Y). According to Danelfin AI, Applied Dna Sciences (BNBX) has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Applied Dna Sciences (BNBX) stock over the past 12 months?

The Applied Dna Sciences (BNBX) stock price range over the past 12 months has been $0.35 - $5.62.

What is going on with Applied Dna Sciences (BNBX) stock in the last 3 months?

The Applied Dna Sciences (BNBX) stock performance in the last quarter has been -42.56%.

Does Applied Dna Sciences (BNBX) offer dividend payments?

No, Applied Dna Sciences (BNBX) does not currently pay dividends.

What is the current market capitalization of Applied Dna Sciences (BNBX)?

Applied Dna Sciences (BNBX)'s market cap is $2.64M, as of 2026-07-02 08:00.

Applied DNA Sciences Inc (BNBX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

BNBX AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Applied DNA Sciences Inc today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 38% probability of outperforming the market in the next 3 months, which is 13% lower than the average probability of any stock (51%). The top positive contributor is the Technicals Impact (Long Tail), which adds +2.88% to the probability, while the top detractors include the Industry (GICS) classification of Life Sciences Tools & Services (-3.34%), Fundamentals Impact (Long Tail) (-1.84%), Chart Pattern (504d) (-1.26%), and the Fear & Greed Index (-1.20%). Notable data points include the stock’s YTD performance in the bottom 10% (down 70.1%), which positively influences the probability, while its 180-day volatility (ATR) is in the top 10% (value 93.42), detracting from the outlook. The Sloan Ratio is also in the top 10% (0.29), indicating lower earnings quality, and Beginning Cash is in the bottom 10% ($2.42M), suggesting limited liquidity. Overall, the strong negative signals from industry, fundamentals, and volatility outweigh the few positive technical factors, resulting in a very low AI Score and a Strong Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Growth+0.50%
Expected pace of revenue and earnings expansion
Momentum+0.37%
Direction and strength of recent price movements

Sentiment-4.58%
How analysts and the market view the stock
Volatility-2.87%
How much the stock price tends to fluctuate
Valuation-2.75%
How the stock is priced relative to its fundamentals
Size & Liquidity-1.16%
Company size and trading liquidity
Profitability-1.05%
Profitability and operating efficiency metrics
Earnings Quality-1.02%
Stability and reliability of reported earnings

BNBX probability advantage of beating the market (3M):

-12.56%

AI Score

Strong Sell

Applied Dna Sciences (BNBX) (BNBX) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -12.56% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of BNBX (38.26%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
BNBX probability advantage of beating the market (3M)-12.56%
BNBX probability of beating the market (3M)38.26%

BNBX probability advantage of beating the market (3M): -12.56%

The AI-powered overall analysis of Applied Dna Sciences (BNBX) (BNBX) is based on the 29 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of BNBX:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Life Sciences Tools & Services	N/A	-3.34%
Technical	Technicals Impact (Long Tail)	-	N/A	+2.88%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-1.84%
Technical	ATR (14d Volatility)	0.06	N/A	+1.29%
Technical	Chart Pattern (504d)	figure_6	N/A	-1.26%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.20%
Technical	ATR (180d Volatility)	93.42		-1.05%
Fundamental	Sloan Ratio	0.29		-1.02%
Technical	Performance (YTD)	-0.70%	N/A	+0.77%
Fundamental	Beginning Cash (Millions)	2.42	N/A	-0.77%
Technical	Upgrade to unlock			-0.76%
Technical	Upgrade to unlock			-0.74%
Technical	Upgrade to unlock			-0.66%
Sentiment	Upgrade to unlock			-0.63%
Fundamental	Upgrade to unlock			-0.59%

Rest of Alpha Signals: -3.66%

BNBX probability advantage of beating the market (3M)Total:-12.56%
BNBX AI Score

Significant changes Vs previous day

BNBX Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$0.37
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

BNBX Proven Sell Signal & Price Forecast

This is the price chart for BNBX from January 1, 2026 until today. The chart indicates, in red, the 112 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

BNBX Average Past Performance & Loss Rate

Three months after its 166 Sell signals since July 2026, BNBX had an average performance of xxxxxxx and a xxxxxxx Loss rate (negative performance).

166 Past BNBX Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

BNBX Frequently Asked Questions

Will Applied Dna Sciences (BNBX) stock go up?
According to Danelfin AI, Applied Dna Sciences (BNBX) has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (38.26%) is -12.56% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Applied Dna Sciences (BNBX) stock?
Is it a good time to buy, sell, or hold Applied Dna Sciences (BNBX) stock right now?
Is Applied Dna Sciences (BNBX) undervalued right now?
What was the price range of Applied Dna Sciences (BNBX) stock over the past 12 months?
What is going on with Applied Dna Sciences (BNBX) stock in the last 3 months?
Does Applied Dna Sciences (BNBX) offer dividend payments?
What is the current market capitalization of Applied Dna Sciences (BNBX)?

Applied DNA Sciences Inc Company Profile

Applied DNA Sciences Inc (BNBX) develops and commercializes DNA-based technology solutions for various industries. These solutions leverage molecular tagging and advanced genetic techniques to address critical needs in supply chain security, anti-counterfeiting, and molecular diagnostics. The company aims to provide verifiable authenticity and traceability for products and materials across global markets, enhancing trust and reducing risks.

The company offers comprehensive product authentication and traceability services designed to protect goods from counterfeiting, diversion, and fraud. It utilizes proprietary DNA markers that provide unique, unalterable identifiers for raw materials, components, and finished products. This technology helps businesses verify the origin and integrity of their items throughout their lifecycle. Its SigNature DNA technology enables forensic authentication at multiple points within a supply chain, helping to ensure product integrity and compliance. The CertainT platform further provides end-to-end traceability and verification for a wide range of products, enhancing transparency and accountability in complex supply chains.

Applied DNA Sciences also operates in the molecular diagnostics domain, providing specialized testing services. These services include PCR-based testing for infectious diseases and other health-related applications, supporting clinical, public health, and industrial needs. Furthermore, the company specializes in the large-scale manufacturing of high-purity DNA through its LinearDNA platform. This platform produces DNA for use in developing vaccines, gene therapies, and advanced diagnostic assays, serving the biotechnology, pharmaceutical, and research sectors with critical genetic material.

The company's solutions are applied across diverse sectors, including textiles, pharmaceuticals, defense, and consumer goods. It serves a broad customer base, including enterprises, government agencies, and healthcare providers. Distribution of its specialized solutions occurs through a combination of direct sales efforts and strategic partnerships. Revenue is generated from product sales, service fees, and licensing agreements, primarily through direct and channel sales to a global customer base.

Sector:Health Care
Country:United States
Industry:
Address:50 Health Sciences Drive, Stony Brook
Employees:26
Website:bnbx.io

Pros

High switching costs for integrated supply chain authentication

Proprietary DNA tagging and detection intellectual property

Increasing regulatory demand for supply chain traceability

Growing market for plasmid-free DNA in gene therapies

Diversified application across multiple industries

Cons

Slow adoption rates due to complex supply chain integration

Competition from alternative anti-counterfeiting technologies

Capital intensity for DNA manufacturing scale-up

Demand cyclicality tied to specific industrial sectors

Potential for technological obsolescence in DNA synthesis methods

Company	AI Score	Compare
ILMNIllumina Inc
XBIOXenetic Biosciences Inc
TWSTTwist Bioscience Corp
QGENQiagen NV
TECHBio-Techne Corp

	Company	AI Score	Compare
1	QSIQuantum-Si Inc
2	QGENQiagen NV
3	MXCTMaxCyte Inc
4	STVNStevanato Group SpA
5	MLABMesa Laboratories Inc
6	SEERSeer Inc
7	EVOEvotec SE
8	NAUTNautilus Biotechnology Inc
9	ICLRICON PLC
10	LABStandard BioTools Inc

Company	AI Score	Compare
ILMNIllumina Inc
XBIOXenetic Biosciences Inc
TWSTTwist Bioscience Corp
QGENQiagen NV
TECHBio-Techne Corp

	Company	AI Score	Compare
1	QSIQuantum-Si Inc
2	QGENQiagen NV
3	MXCTMaxCyte Inc
4	STVNStevanato Group SpA
5	MLABMesa Laboratories Inc
6	SEERSeer Inc
7	EVOEvotec SE
8	NAUTNautilus Biotechnology Inc
9	ICLRICON PLC
10	LABStandard BioTools Inc

BNBX Stock AI Analysis High Risk